Barclays Maintains Overweight on Regenxbio, Lowers Price Target to $12
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Gena Wang maintains Regenxbio (NASDAQ:RGNX) with a Overweight and lowers the price target from $37 to $12.
Barclays analyst Gena Wang maintains Regenxbio (NASDAQ:RGNX) with a Overweight and lowers the price target from $37 to $12.